Navigation Links
ATCC Examined the Importance of High-quality Controls in Assay Design and Development During the Association for Molecular Pathology (AMP) 2013 Annual Meeting
Date:11/25/2013

Manassas, VA (PRWEB) November 25, 2013

The use of well-defined controls in assay development is essential for determining the reliability and reproducibility of data obtained from molecular applications. ATCC spoke out on this topic during its first participation at the Corporate Workshop Day at the AMP 2013 Annual Meeting, emphasizing the importance of using authenticated and highly characterized biomaterials for assay development and verification. More than 75 researchers from pharmaceutical and molecular diagnostics companies attended the workshop. The presentation was divided into two parts, first focusing on controls for genetic mutations in cancer biology, followed by a discussion on the detailed characterization of ATCC infectious disease strains and nucleic acid controls.

Fang Tian, Ph.D., Lead Scientist for ATCC Cell Systems, led the discussion by describing the rapidly changing landscape of diagnostics, including the vast amount of human genetic data currently available via open-access. Moreover, with the development of smaller, faster, and more affordable sequencing technologies, investigators now require a stable and renewable source of controls, such as fully characterized and authenticated cell lines. To meet these needs, ATCC organized Tumor Cell Panels representing cell lines grouped by tissue type and annotated with published gene mutation data. Further, Dr. Tian explained, “ATCC is not only pairing cell lines with published gene mutation data, we are also performing extensive laboratory analyses to confirm the presence, stability, and expression of genetic mutations using tools like sequencing, PCR, and Western Blot.”

Liz Kerrigan, Director of Standards at ATCC noted, “There are a lot of choices for controls in research, but it’s imperative to obtain controls from a reliable source; knowing how they were produced and how identities were verified – that’s the importance of authentication.” ATCC
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Alternatives to Medicares fee-for-service payment system examined
2. Implant Overdentures - Dr. Jonathan Penchas Has Examined Studies That Show a High Success Rate and Advantages over Long Period
3. Ultrasound Systems Market Examined by GBI Research in New Insightful Report Now Available at MarketPublishers.com
4. Age Old Problem is Examined in New Book
5. Black American Obesity Examined In The Latest FinancesOnline.com Article
6. US POCT Market Examined & Forecast by VPG in New In-Demand Report Available at MarketPublishers.com
7. Colon Cleanse for Adults Over 40 Years of Age Now Examined Online at eHealthMax.com
8. Internal Hemorrhoids At-Home Treatments for Adults Over 40 Now Examined Online by eHealthMax.com
9. Natural Ways to Lower Cholesterol Now Examined for Adults Over 40 at eHealthMax.com
10. North American Drug Delivery Systems Market Examined by MarketsandMarkets in Topical Study Available at MarketPublishers.com
11. Eye Lash Extension Products Now Examined for Ladies at eHealthMax.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... BeverlyD, ... for the March4thforWellBeing foundation, making hers the very first small business donation to kick ... look beautiful for over thirty years. Her legacy includes a complete line of raw, ...
(Date:7/31/2015)... NV (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable source ... at the MGM Grand Garden Arena. Fans of every genre of music will have ... September 18th, the first day of the festival, the following artists will perform: Sam ...
(Date:7/31/2015)... ... 2015 , ... Ticket Down is a reliable source for authentic tickets for ... Park. The festival will end on Sunday, August 2nd. , Music ... Lollapalooza. This unique and unbelievably popular festival attracts the best in entertainment from ...
(Date:7/31/2015)... ... 2015 , ... The 2nd annual Ride to Fight On will start and ... 2015. The Ride to Fight On is a cycling fundraiser that benefits the West ... Clinic and The University of Tennessee Health Science Center. A health and wellness festival ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin ... re-branded their social media profiles to better connect with the public. The agency ... find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to ...
Breaking Medicine News(10 mins):Health News:March4thforWellBeing Foundation Kickoff 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2
... ST. PAUL, Minn., Sept. 10 . Two heroes of ... New York,s Hudson River last January will visit the Twin Cities ... fundraiser. , , Patrick Harten , the ... choose an emergency response, and cool-headed flight attendant Doreen Welsh ...
... MALVERN, Pa., Sept. 10 Ascenta Therapeutics announced today that following ... its Investigational New Drug (IND) Application for AT-406, an orally-active, small ... trial in patients with advanced cancer during the fourth quarter of ... ) , , "We are very pleased ...
... TORONTO, Sept. 10 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: ... the global life sciences markets, today reported financial results for the ... $199 million, a net loss of $62 million and a loss ... with $252 million in total revenue, a net loss of $10 ...
... , ARMONK, N.Y., Sept. 10 ... (CIOs), released by IBM (NYSE: IBM ) today, ... business decision-making is now the top priority for CIOs. More than ... and analytics - the ability to see patterns in vast amounts ...
... , , LONG BEACH, Calif., Sept. 10 ... this system is you. All I ask in return for using my system ... said Bob Ainuu Afamasaga. , , "Millions of Europeans ... mind because, as I have already said several times, creating debt is no solution..." ...
... ... Shepherd presented at this year,s Pennsylvania Association for Justice (PaAJ) "Pennsylvania Master Series, ... , ... PA (PRWEB) September 10, 2009 -- Feldman, Shepherd, Wohlgelernter, Tanner, Weinstock & Dodig ...
Cached Medicine News:Health News:Wings of Mercy Benefit Features 'Miracle on the Hudson' Heroes 2Health News:Wings of Mercy Benefit Features 'Miracle on the Hudson' Heroes 3Health News:Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406 2Health News:MDS Reports Third Quarter 2009 Financial Results 2Health News:MDS Reports Third Quarter 2009 Financial Results 3Health News:MDS Reports Third Quarter 2009 Financial Results 4Health News:MDS Reports Third Quarter 2009 Financial Results 5Health News:MDS Reports Third Quarter 2009 Financial Results 6Health News:MDS Reports Third Quarter 2009 Financial Results 7Health News:MDS Reports Third Quarter 2009 Financial Results 8Health News:MDS Reports Third Quarter 2009 Financial Results 9Health News:MDS Reports Third Quarter 2009 Financial Results 10Health News:MDS Reports Third Quarter 2009 Financial Results 11Health News:MDS Reports Third Quarter 2009 Financial Results 12Health News:MDS Reports Third Quarter 2009 Financial Results 13Health News:MDS Reports Third Quarter 2009 Financial Results 14Health News:MDS Reports Third Quarter 2009 Financial Results 15Health News:MDS Reports Third Quarter 2009 Financial Results 16Health News:MDS Reports Third Quarter 2009 Financial Results 17Health News:MDS Reports Third Quarter 2009 Financial Results 18Health News:MDS Reports Third Quarter 2009 Financial Results 19Health News:MDS Reports Third Quarter 2009 Financial Results 20Health News:MDS Reports Third Quarter 2009 Financial Results 21Health News:MDS Reports Third Quarter 2009 Financial Results 22Health News:MDS Reports Third Quarter 2009 Financial Results 23Health News:New IBM Study Highlights Analytics as Top Priority for Today's CIO 2Health News:New IBM Study Highlights Analytics as Top Priority for Today's CIO 3Health News:New IBM Study Highlights Analytics as Top Priority for Today's CIO 4Health News:$0.00 Penny System to Jump Start Global Economy Developed by DNA and MIND Researcher. 2Health News:Philadelphia Attorney Carol Nelson Shepherd Presents at the 2009 Pennsylvania Association for Justice Master Series 2
(Date:7/30/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today ... Agreements with Dexcom, Inc. to allow the integration ... Dexcom G5 and G6 continuous glucose monitoring ("CGM") ... platform with Dexcom,s future CGM systems is an ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... 2010 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) ... trial.  The Company has now completed the final trial necessary ... plans to submit an NDA in the first half of ... has completed Phase 3 clinical development for the acute treatment ...
... Inc. today announced $3 million in Convertible Note funding. ... Phase II trials of BPX-101, the company,s DeCIDe™ vaccine ... a cell therapy safety switch under initial development in ... The new funding brings the total raised to date ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 2MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 3Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: